# Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin

> **NCT00977717** · — · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Curatively Resected Stage III Colon Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00977717
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2010-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977717, "Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00977717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*